Previous 10 | Next 10 |
SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing partner for its preclinical candidate, IMP761, has made significant progress...
Obalon Therapeutics (NASDAQ: OBLN ) -25% . More news on: Obalon Therapeutics, Inc., NeuroMetrix, Inc., Cocrystal Pharma, Inc., Stocks on the move, , Read more ...
SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACT...
SYDNEY, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plans to conti...
Gainers: Astrotech (NASDAQ: ASTC ) +425% . More news on: Astrotech Corporation, T2 Biosystems, Inc., BroadVision, Inc., Stocks on the move, , Read more ...
Immutep (NASDAQ: IMMP ) -46% on underwhelming efti data. More news on: Immutep Limited, IMAC Holdings, Inc., ThermoGenesis Holdings, Inc., Stocks on the move, , Read more ...
Thinly traded nano cap Immutep Limited (NASDAQ: IMMP ) slumps 45% premarket on light volume in reaction to results from a Phase 2b clinical trial, AIPAC , evaluating lead drug eftilagimod alfa (efti), combined with chemo agent paclitaxel, in patients with HER2-negative/Hormone...
Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus placebo at the 6-month landmark Increased Overall Response Rate (ORR) of 48.3% in the efti group versus 38.4% in the placebo group Immutep will advance discussions with regulatory authoriti...
Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma’s phase I study in metastatic breast cancer (MBC) Data expected throughout 2020, with study completion in Q4 CY2020 Registration trial in MBC in China is planned SYDNEY, Australia, March 19, 2...
Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancer AIPAC-002 to expedite the possible use of efti for patients in the US SYDNEY, Australia, March 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “t...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...